Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet

Diabetes Research and Clinical Practice

Volumn 81, Issue 2, 2008, Pages 134-143

  Shih, Chun Ching ^a   Lin, Cheng Hsiu ^b   Lin, Wei Li ^c  

^a CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b FENG YUAN HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Insulin resistance; Leptin; Momordica charantia; Resistin

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; MESSENGER RNA; MOMORDICA CHARANTIA EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL RAT; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; HYPERLEPTINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; MALE; MOMORDICA CHARANTIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD GLUCOSE; DIET, FAT-RESTRICTED; DIETARY FATS; DNA, COMPLEMENTARY; FRUIT; GENE EXPRESSION REGULATION; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPIDS; MICE; MICE, INBRED C57BL; MOMORDICA CHARANTIA; OBESITY; POLYMERASE CHAIN REACTION; PPAR ALPHA; RNA, MESSENGER;

EID: 47849123027     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.023     Document Type: Article

References (62)

1. Astrup A., Buemann B., Western P., Toubro S., Raben A., and Christensen N.J. Obesity as an adaptation to a high-fat diet: evidence from a cross-sectional study. Am. J. Clin. Nutr. 59 (1994) 350-355
2. Strorlien L.H., Kriketos A.D., Jenkins A.B., Baur L.A., Pan D.A., Tapsell L.C., et al. Does dietary fat influence insulin action?. Ann. N. Y. Acad. Sci. 827 (1997) 287-301
3. Ahren B., Simonsson E., Scheurink A.J., Mulder H., Myrsen U., and Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46 (1997) 97-106
4. Ahren B. Plasma leptin and insulin in C57BL/6J mice on a high-fat diet: relation to subsequent changes in body weight. Acta Physiol. Scand. 165 (1999) 233-240
5. Lillioja S., Mott D.M., Howard V., Bennett P.H., Hannele Y.J., Freymond D., et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and crosssectional studies in Pima Indians. N. Engl. J. Med. 318 (1988) 1217-1224
6. O'Rahilly S., Turner R.C., and Matthews D.R. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N. Engl. J. Med. 318 (1988) 1225-1230
7. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
8. Kobayashi M., Ohno T., Tsuchiya T., and Horio F. Characterization of diabetes-related traits in MSM and JF1 mice on high-fat diet. J. Nutr. Biochem. 15 (2004) 614-621
9. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., and Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37 (1988) 1163-1167
10. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat; possible contributor to vascular disease in obesity. Nat. Med. (1996) 800-803
11. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
12. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-317
13. Rangwala S.M., and Lazar M.A. Perxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 25 (2004) 331-336
14. Cabrero A., Alegret M., Scanchez R.M., Adzet T., Laguna J.C., and Vazquez M. Bezafibrate reduces mRNA levels of adipocyte makers increases fatty acid oxidation in primary culture of adipocytes. Diabetes 50 (2001) 1883-1890
15. Karunanayake E.H., and Tennekoon K.H. Search of novel hypoglycaemic agents from medicinal plants. In: Sharma A.K. (Ed). Diabetes Mellitus and Its Complications, An Update (1993), Macmillan India Ltd., New Delhi, India 192-205
16. Department of Health, Executive Yuan, Taiwan, Food Composition and Analysis in Taiwan, 1998.
17. Akhtar M.S., Athar M.A., and Yaqub M. Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbit. Planta Med. 42 (1981) 205-212
18. Srivastava Y., Bhatt H.V., Verma Y., and Prem A.S. Retardation of retinopathy by Momordica charantia Linn. (bitter gourd) fruit extract in alloxan diabetic rats. Indian J. Exp. Biol. 25 (1987) 571-572
19. Day C., Cartwright T.J., and Bailey C.J. Hypoglycemic effect of Momordica charantia extracts. Planta Med. 56 (1990) 426-429
20. Pugazhenthi S., and Murthy S.P. Partial purification of a hypoglycemic fraction from the unripe fruits of Momordica charantia Linn. Indian J. Clin. Biochem. 10 (1995) 19-22
21. Platel K., Shurpalekar K.S., and Srinivasan K. Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung 37 (1993) 156-160
22. Raman A., and Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 2 (1996) 349-362
23. Grover J.K., and Yadav S.P. Pharmacological actions and potential uses of Momordica charantia: a review. J. Ethnopharmacol. 93 (2004) 123-132
24. Khanna P., Jain S.C., Panagariya A., and Dixit V.P. Hypoglycemic activity of polypeptide-p from a plant source. J. Nat. Prod. 44 (1981) 648-655
25. Lotlikar M.M., and Rao M.R. Pharmacology of a hypoglycemic principle isolated from the fruits of Momordica charantia Linn. Indian J. Pharm. 28 (1996) 129
26. Matsuda H., Li Y., Murajami T., Matsumura N., Yamahara J., and Yoshikawa M. Antidiabetic principles of natural medicines, Part III. Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Chem. Pharm. Bull. (Tokyo) 46 (1998) 1399-1403
27. Chen Q., Chan L.L.Y., and Li E.T.S. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizers glucose tolerance in rats fed a high fat diet. J. Nutr. 133 (2003) 1088-1093
28. Lundasen T., Hunt M.C., Nilsson L.-M., Sanyal S., Angelin B., Alexson S.E.H., et al. PPARα is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 260 (2007) 437-440
29. Muraakami T., Emoto A., Matsuda H., and Yoshikawa M. Medicinal foodstuffs. XXI. Structures of new Cucurbitane-triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and new oleanane-type triterpene saponins, goyasaponin I, II, and III, from the fresh fruit of Japaneses Momordica charantia L. Chem. Pharm. Bull. 49 (2001) 54-63
30. Surwit R.S., Petro A., and Parekh P. Low plasma leptin in response to dietary fat in diabetes- and obesity-prone mice. Diabetes 46 (1997) 9, 1516-1520
31. Eckel R.H. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic disease. N. Engl. J. Med. 320 (1989) 1060-1068
32. Rothwell N.J., and Stock M.J. A role for brown adipose tissue in diet-induced thermogenesis. Nature 281 (1979) 31-35
33. Verges B. Clinical interest of PPARs ligands: particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab. 30 (2004) 7-12
34. Chawla A., Schwarz E.J., Dimaculangan D.D., and Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135 (1994) 798-800
35. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription. Cell 79 (1994) 1147-1156
36. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. Biol. 4 (1999) 597-609
37. Sood V., Colleran K., and Burge M.R. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol. Ther. 2 (2000) 429-449
38. Lee C.H., Olson P., and Evans R.M. Mini review: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptor. Endocrinology 144 (2003) 2201-2207
39. Minokoshi Y., Haque M.S., and Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48 (1999) 287-291
40. Perez C., Fernandez-Galaz C., Fernandez-Agullo T., Arribas C., Andres A., Ros M., et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 53 (2004) 347-353
41. Kallen C.B., and Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5793-5796
42. Vos P.D., Lefebvre A.M., Miller S.G., Guerre-Millo M., Wong K., Saladin R., et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferators-activated receptor gamma. J. Clin. Invest. 98 (1996) 1004-1009
43. Hollenberg A.N., Susulic V.S., Madura J.P., Zhang B., Moller D.E., Tontonoz P., et al. Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. J. Biol. Chem. 272 (1997) 5283-5290
44. Jacobson L. Middle-aged C57BL/6 mice have impaired responses to leptin that are not improved by calorie restriction. Am. J. Physiol. Endocrinol. Metab. 282 (2002) E786-E793
45. El-Haschimi K., Pierroz D.D., Hileman S.M., Bjorbaek C., and Flier J.S. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest. 105 (2000) 1827-1832
46. Lin L., Martin R., Schaffhauser A.O., and York D.A. Acute changes in the response to peripheral leptin with alteration in the diet composition. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 (2001) R504-R509
47. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., and Nyce M.R. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
48. Kissebah A.H. Central obesity: measurement and metabolic effects. Diabetes Rev. 5 (1997) 8-20
49. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101 (1998) 1354-1361
50. Akawaza S., Sun F., Ito M., Kawasaki E., and Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23 (2000) 1067-1071
51. Bjorntorp P. Visceral obesity: a civilisation syndrome. Obes. Res. 1 (1993) 206-222
52. Kissebah A., Vydelingum N., and Murray R. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Clin. Endocrinol. Metab. 54 (1982) 254-260
53. Kovacs P., and Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract. Res. Clin. Endocrinol. Metab. 19 4 (2005) 625-635
54. Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., et al. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270 (1995) 19269-19276
55. Reddy J.K., and Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21 (2001) 193-230
56. Ersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103 (1999) 1489-1498
57. Chou C.J., Haluzik M., Gregory C., Dietz K.R., Vinson C., Gavrilova O., et al. WY 14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. 277 (2002) 24484-24489
58. Kim H., Haluzik M., Asghar Z., Yau D., Joseph J.W., Fernandez A.M., et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52 (2003) 1770-1778
59. Sugden M.C., and Holness M.J. Potential role of peroxisome proliferator-activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. Diabetes 53 (2004) S71-S81
60. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and liproprotein metabolism. Circulation 98 (1998) 2088-2093
61. Unger R.H., and Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disorder 24 Suppl. 4 (2001) S28-S32
62. Bourgeois F., Alexiu A., and Lemonnier D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice. Br. J. Nutr. 49 (1983) 17-26